arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Clene Inc.

CLNN
$4.33 ▼ -0.11 (-2.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Clene Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $53.6M
Dividend Yield
Revenue Growth 233.3%
Op. Margin
ROIC 74.5%
FCF / Share $-0.21
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.71
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$90.00K
↑ +233.3%
Net Income Profit after all expenses
$-8.09M
↓ -977.4%
FCF / Share Free cash flow per share
$-0.21
↑ +46.3%
Long-Term Debt Long-term obligations
$17.60M
↓ -0.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
66
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters